FDA Launches New Ultra-Rare Disease Therapy Framework

The U.S. Food and Drug Administration (FDA) introduced the Plausible Mechanism Framework on March 5, 2026 ^[1]. This regulatory shift aims to accelerate the approval of highly targeted therapies for patients with ultra-rare diseases ^[1]. Traditional large-scale clinical trials are often impossible for these extremely small patient populations ^[1]. Under the new framework, regulators will consider biological plausibility and AI-enhanced trial designs for drug approvals ^[1]. This approach allows for evidence-based decisions when standard data collection methods are not feasible ^[1]. The initiative represents a significant step forward in the delivery of individualized medicine for those with limited treatment options ^[1].